Chris de Beer-Procter Memorial Day weekend 2026 is shaping up as a Star Wars-driven period for the U.S. box office, with Disney ( DIS ) and Lucasfilm’s Star Wars: The Mandalorian & Grogu widely expected to dominate. Early projections are clustered around the $80M to $90M mark for the four-day domestic debut, with some independent forecasts stretching into a low-nine-figure range. Globally, the fil...
Chris de Beer-Procter Memorial Day weekend 2026 is shaping up as a Star Wars-driven period for the U.S. box office, with Disney ( DIS ) and Lucasfilm’s Star Wars: The Mandalorian & Grogu widely expected to dominate. Early projections are clustered around the $80M to $90M mark for the four-day domestic debut, with some independent forecasts stretching into a low-nine-figure range. Globally, the film is projected to open in the neighborhood of $160M, with about half of that total expected from overseas markets where it is rolling out across roughly 98% of territories this weekend. The film is the first Star Wars theatrical release since 2019. Notably, the U.S. box office was up 23% in Q1 and rose 11.1% halfway through the second quarter. Looking ahead, Texas Capital analyst Eric World advised that the remaining film slate for Q2 is relatively attractive, with several movies with potential upside outside the Star Wars return. Other releases during June include Scary Movie 6 (the first release in that franchise since 2013), Toy Story 5 (the first release in that franchise since 2019), and Steven Spielberg's highly anticipated Disclosure Day, which is arriving amid near-viral interest in UFOs. The holiday weekend arrives at a busy time for the movie studio and movie theater sectors. AMC Entertainment ( AMC ) rallied more than 20% during the week after CEO Adam Aron snapped up more shares, while IMAX ( IMAX ) is on the move amid buyout talks. Lionsgate Studios ( LION ) jumped 7.7% on Friday after an earnings topper, and investors are watching for signs of regulatory pushback against the Paramount Skydance ( PSKY ) buyout of Warner Bros. Discovery ( WBD ). Meanwhile, Marcus Corporation ( MCS ) is sitting under the radar as the only movie-related stock with a clean sweep of bull ratings across Seeking Alpha analysts, Wall Street analysts, and the quant ratings system. More on movie-related stocks AMC Entertainment: Dead Cat Bounce IMAX Corporation (IMAX) Presents at J.P. Mo...
Tom Werner/DigitalVision via Getty Images A Quick Take On The Parabilis Medicines IPO Parabilis Medicines, Inc. ( PBLS ) has filed to raise drug development funding via an IPO, according to an S-1 registration statement . The company is a clinical-stage biopharma developing helicon peptide-based treatments for various types of cancers. PBLS has seen positive Phase 1 safety and dosing trial results...
Tom Werner/DigitalVision via Getty Images A Quick Take On The Parabilis Medicines IPO Parabilis Medicines, Inc. ( PBLS ) has filed to raise drug development funding via an IPO, according to an S-1 registration statement . The company is a clinical-stage biopharma developing helicon peptide-based treatments for various types of cancers. PBLS has seen positive Phase 1 safety and dosing trial results, and management believes its Phase 2 results will support a Phase 3 trial in the near future. Given the firm’s promising results, strong financial backing and relationship with Regeneron Pharmaceuticals, the IPO will likely be in high demand by institutional life science investors. Parabilis’ Overview And Development Efforts The company is developing treatments for desmoid tumors, other tumor types, and colorectal cancer. It is focused on Helicon peptide treatments that target the interaction between β-catenin and the T-cell factor signaling pathway, whose activation drives millions of cancer cases through various cancer subtypes. Management believes that “an estimated 80% of biologically validated disease targets are considered undruggable, largely because the majority reside inside cells and present flat interaction surfaces. Small molecules can enter cells but cannot bind flat surfaces, and antibodies and other highly-selective biologics can selectively bind flat protein surfaces but cannot enter cells to access these targets. To our knowledge, Helicons are the only modality to date with the potential to consistently solve this problem as they are engineered for cell penetration and capable of binding to flat intracellular protein target surfaces with high specificity.” Parabilis’ lead candidate, zolucatetide, is in Phase 2 or 1 trials for five different cancer types, as the pipeline graphic shows here: SEC Initial trial results for the treatment of desmoid tumors have shown zolucatetide is “well tolerated across the therapeutic dose range,” and management believes that...
We look to open the final trading day for the week higher, after a Thursday session in the green that brought the blue-chip Dow to all-time closing highs. Promises of an end to the war in Iran joins anticipation over the pending SpaceX IPO, which is expected to blow away all other market launches with a reported $2 TRILLION market cap. The Dow is up another +340 points, the S&P 500 is +28, the Nas...
We look to open the final trading day for the week higher, after a Thursday session in the green that brought the blue-chip Dow to all-time closing highs. Promises of an end to the war in Iran joins anticipation over the pending SpaceX IPO, which is expected to blow away all other market launches with a reported $2 TRILLION market cap. The Dow is up another +340 points, the S&P 500 is +28, the Nasdaq +106 and the small-cap Russell 2000 is +17 points currently. It was a quieter week of earnings reports, even with NVIDIA NVDA and Walmart WMT having put out quarterly numbers Wednesday and Thursday, respectively. We also saw economic reports that, while less “important” than the CPI Inflation Rate we saw a week ago or the Jobs Week coming a couple weeks from now, helped illustrate where we are on the housing front and in consumer outlook. Economic Report Rundown: Housing and Consumer Trends Homebuilder confidence improved slightly for May, but off dismal levels from the prior month — when the realities of the Iran war had begun to cumulatively take hold. Pending Home Sales for April came in higher than estimates, but still down a tad month over month. Housing Starts and Building Permits only saw growth on Multi-family; Single-family homebuilding remained recessed for the month. May S&P Services and Manufacturing reports yesterday moved in opposing directions, but likely not what you’d think: Services dipped 10 basis points (bps) to 50.9 — still holding onto that above-50 threshold for now — while Manufacturing saw a boost up to 55.3, nicely higher than the projected 53.7 and up 80 bps month over month. After today’s opening bell, we’ll get the final print on U.S. Consumer Sentiment for May from the University of Michigan household survey. Initially, we saw an all-time low 48.2 — only the second straight sub-50 level in this index’s 74-year history. Consumer Sentiment is -3.21% month over month and -7.66% year over year, as ever-increasing gasoline prices have put a dent...
Jacques LOIC An expert panel of the EU drug regulator endorsed eight new medicines for approval this week, including new indications for Merck's ( MRK ) and AstraZeneca's cancer drugs Keytruda and Enhertu, as well as AbbVie’s ( ABBV ) hepatitis C therapy, Maviret. AbbVie The company announced on Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued ...
Jacques LOIC An expert panel of the EU drug regulator endorsed eight new medicines for approval this week, including new indications for Merck's ( MRK ) and AstraZeneca's cancer drugs Keytruda and Enhertu, as well as AbbVie’s ( ABBV ) hepatitis C therapy, Maviret. AbbVie The company announced on Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on Maviret for people aged three years and older with acute hepatitis C infection. The antiviral agent is currently available in the region for the chronic HCV infection. A final authorization decision is expected from the European Commission in Q3 2026. Additionally, the CHMP issued a positive opinion on the company’s anti-wrinkle therapy Boey as a treatment for the temporary improvement of glabellar lines, commonly known as frown lines. A final decision on that approval is expected in the coming months. Merck The New Jersey-based drugmaker announced on Friday that the CHMP issued a positive opinion on anti-PD-1 therapy Keytruda as part of a combination regimen with Pfizer ( PFE ) and Astellas ( ALPMF ) ( ALPMY ) Padcev for muscle-invasive bladder cancer that cannot be surgically removed. Specifically, the endorsement calls for the use of Keytruda with Padcev initially as a neoadjuvant option, followed by adjuvant treatment for adults with resectable MIBC for whom cisplatin-containing chemotherapy is not indicated. A final decision is expected by Q3 2026. AstraZeneca The Anglo-Swedish drugmaker’s antibody drug conjugate Enhertu, developed with Japan’s Daiichi Sankyo ( DSKYF ) ( DSNKY ), was endorsed by the CHMP as a late-line monotherapy for certain adults with HER2-positive solid tumors. Multiple regulatory submissions for the HER2-directed therapy are under review in the EU, including as a combination therapy for patients with newly diagnosed HER2-positive breast cancer, the company said. Gilead Gilead ( GILD ) announced that CHMP issued a positive opi...
Seven Bangladeshi-Italian candidates stand for Venice’s council as community faces far-right hostility – while voters demand an end to overtourism and neglect Rhitu Miah, one of seven candidates from the Bangladeshi-Italian community standing in Venice’s local election, is used to brushing off racist or sexist comments. But she was taken aback by the virulence of the negative comments online when ...
Seven Bangladeshi-Italian candidates stand for Venice’s council as community faces far-right hostility – while voters demand an end to overtourism and neglect Rhitu Miah, one of seven candidates from the Bangladeshi-Italian community standing in Venice’s local election, is used to brushing off racist or sexist comments. But she was taken aback by the virulence of the negative comments online when she announced she would run for the council – potentially making her one of the first people of Bangladeshi origin ever elected in the lagoon city’s administration. “There were hateful messages – one person told me to get on a camel and go back to my own country,” says Miah, an Italian citizen who moved to Venice with her family at aged three through her father’s job at the Fincantieri shipyard, a huge importer of labour from Bangladesh. “I tried to let it be and reply with a smile … but it was difficult not to cry. This is also a reason why I’m running [to combat these prejudices].” Continue reading...
Worawith Ounpeng Construction company RUI Holdings has filed a preliminary prospectus for an initial public offering of 4M class A shares. The IPO price is currently estimated to be in the range of $4.00-$5.00 per share, representing proceeds of up to $20M. The Cayman Islands-based company has applied to list the shares on Nasdaq under the ticker symbol RUIH. About 40% of the proceeds are intended...
Worawith Ounpeng Construction company RUI Holdings has filed a preliminary prospectus for an initial public offering of 4M class A shares. The IPO price is currently estimated to be in the range of $4.00-$5.00 per share, representing proceeds of up to $20M. The Cayman Islands-based company has applied to list the shares on Nasdaq under the ticker symbol RUIH. About 40% of the proceeds are intended to be used for market expansion and sales channels, ~30% for technology development, and roughly 30% for working capital and general corporate purposes. For the fiscal year ended August 31, 2025, RUI's revenue had totaled $13.67M, up ~335% from fiscal 2024. The company had reported a net income of $42,441, compared to a loss of $71,539 in the prior year. More on IPOs North Carolina-based First Carolina Financial Services files for IPO SA Asks: What's a good alternative investment to SpaceX? Blockchain.com confidentially submits draft registration statement for IPO
Andrii Dodonov/iStock via Getty Images SPY vs. SPYI: Muted market volatility unlikely to last I last covered the NEOS S&P 500 High Income ETF ( SPYI ) on January 27, 2026 with an article titled “SPYI Vs. QQQI: Why I Prefer The SP500-Based Covered Fund”. The article focused on the valuation and risk dynamics between the S&P 500 and NASDAQ indices. It concluded with a buy rating for SPYI. Since then...
Andrii Dodonov/iStock via Getty Images SPY vs. SPYI: Muted market volatility unlikely to last I last covered the NEOS S&P 500 High Income ETF ( SPYI ) on January 27, 2026 with an article titled “SPYI Vs. QQQI: Why I Prefer The SP500-Based Covered Fund”. The article focused on the valuation and risk dynamics between the S&P 500 and NASDAQ indices. It concluded with a buy rating for SPYI. Since then, there have been several material changes both in terms of macroscopic economic conditions, geopolitics and also fund specifics such as holdings and dividends. The rest of this article will concentrate on the top three changes in my view. In terms of fund specifics, I will focus on the latest dividend payouts announced by the SPYI ETF to argue why these payout changes could suggest attractive valuation for SPYI when compared to its underlying index, which will be approximated by the State Street SPDR S&P 500 ETF Trust ( SPY ) here. In terms of macroeconomics, I will focus on the changes of the implied volatility (IV) in the option market and also the changes of the interest rate outlook. My key takeaways on this front are twofold. First, I consider the current volatility an underestimate of the true uncertainties underneath the SPY. In other words, I consider the current S&P 500 volatility, as measured by the VIX index below, to be too muted to last. Second, I expect the new interest rate outlook to pressure the valuation of SPY more than SPYI. With the above considerations, I see a large alpha potential in SPYI relative to SPY and thus keep my buy rating for the SPYI ETF. Seeking Alpha SPYI and SPY: basic information Before going into further details, let me take a quick digress to cover the basics of these ETFs first. SPY requires little introduction and I imagine the following one-sentence quote from its fund description homepage should be all I need here. SPY Fund description: The fund tracks the massively popular US index, the S&P 500. The index offers outstanding exp...
On May 19, 2026, Rovida Investment Management Ltd disclosed a new stake in H World Group Limited (NASDAQ:HTHT) , purchasing 200,000 shares in a trade estimated at $10.20 million based on quarterly average pricing. According to a U.S. Securities and Exchange Commission (SEC) filing dated May 19, 2026, Rovida Investment Management initiated a new position in H World Group Limited by purchasing 200,0...
On May 19, 2026, Rovida Investment Management Ltd disclosed a new stake in H World Group Limited (NASDAQ:HTHT) , purchasing 200,000 shares in a trade estimated at $10.20 million based on quarterly average pricing. According to a U.S. Securities and Exchange Commission (SEC) filing dated May 19, 2026, Rovida Investment Management initiated a new position in H World Group Limited by purchasing 200,000 shares. The estimated transaction value was $10.20 million, calculated using the quarter’s average unadjusted close. The quarter-end position was valued at $10.06 million, a figure that reflects both the fund’s purchase and subsequent stock price movements during the period. H World Group Limited operates hotels under a diverse set of brands spanning economy to luxury segments. The company leverages a scalable franchise and management platform to expand its footprint while maintaining strong brand recognition and customer loyalty. Its broad portfolio and hybrid business model provide resilience and growth opportunities in a dynamic travel market. Continue reading
On this episode of Stock Movers with Alexis Christoforous: - Estee Lauder (EL) share are climbing following collapse of a proposed combination with Puig Brands that would have created one of the world’s largest fragrance and skincare companies. - IMAX Corp. (IMAX) shares jumped after the Wall Street Journal reported the large-screen theater company is exploring a sale and has approached entertainm...
On this episode of Stock Movers with Alexis Christoforous: - Estee Lauder (EL) share are climbing following collapse of a proposed combination with Puig Brands that would have created one of the world’s largest fragrance and skincare companies. - IMAX Corp. (IMAX) shares jumped after the Wall Street Journal reported the large-screen theater company is exploring a sale and has approached entertainment companies as potential buyers. - Ross Stores (ROST) shares are up after the off-price retailer boosted its comparable sales forecast for the full year. The firm also posted better-than-expected sales for the first quarter. (Source: Bloomberg)
Chinese AI firms MiniMax Group and Knowledge Atlas Technology – better known as Zhipu AI – will join the Hang Seng Tech Index next month. Their inclusion follows investor criticism that the city’s primary technology gauge has underperformed by missing out on the global artificial intelligence boom Concurrently, Shanghai-based courier J&T Global Express, lightweight metal giant Aluminum Corp of Chi...
Chinese AI firms MiniMax Group and Knowledge Atlas Technology – better known as Zhipu AI – will join the Hang Seng Tech Index next month. Their inclusion follows investor criticism that the city’s primary technology gauge has underperformed by missing out on the global artificial intelligence boom Concurrently, Shanghai-based courier J&T Global Express, lightweight metal giant Aluminum Corp of China and Beijing-founded global drug firm BeOne Medicines will join the benchmark Hang Seng Index. The additions are part of a long-term plan by the compiler to increase the number of blue-chip constituents to 100. Advertisement The three companies will be added to the gauge after the market close on June 5, increasing the tally of index constituents to 93 from 90 currently, Hang Seng Indexes Co said in a statement on Friday after the market closed. Meanwhile, there will be no deletions, it said. Meanwhile, Hansoh Pharmaceutical and Akeso will join the Hang Seng China Enterprises Index of mainland Chinese companies trading in Hong Kong, according to the statement. 02:14 Young Chinese professionals embrace ‘solopreneurship’ amid AI job anxiety The Hang Seng Index has remained little changed this year after a 28 per cent gain that made it one of the world’s best-performing equity benchmarks in 2025. The energy shock stemming from the drawn-out US-Israel war on Iran and concerns about weak results from China’s big tech platforms have weighed on investors’ sentiment.
In early trading on Friday, shares of Estee Lauder topped the list of the day's best performing components of the S&P 500 index, trading up 11.9%. Year to date, Estee Lauder has lost about 15.7% of its value. And the worst performing S&P 500 component thus far on the day is Bank of New York Mellon, trading down 92.5%. Bank of New York Mellon is lower by about 91.2% looking at the year to date perf...
In early trading on Friday, shares of Estee Lauder topped the list of the day's best performing components of the S&P 500 index, trading up 11.9%. Year to date, Estee Lauder has lost about 15.7% of its value. And the worst performing S&P 500 component thus far on the day is Bank of New York Mellon, trading down 92.5%. Bank of New York Mellon is lower by about 91.2% looking at the year to date performance. Two other components making moves today are SanDisk, trading down 2.8%, and Dell Technologies, trading up 10.1% on the day. VIDEO: S&P 500 Movers: BK, EL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
00:00 Speaker A Well, quantum stocks surged yesterday, and that was on an announcement that the US government plans to award two billion dollars in grants to nine firms in the space. 00:10 Speaker A Different kinds of grants for these different kinds of companies. The stocks continue to go higher today. 00:17 Speaker A But here is how it's going to work. IBM is going to get a billion dollars to es...
00:00 Speaker A Well, quantum stocks surged yesterday, and that was on an announcement that the US government plans to award two billion dollars in grants to nine firms in the space. 00:10 Speaker A Different kinds of grants for these different kinds of companies. The stocks continue to go higher today. 00:17 Speaker A But here is how it's going to work. IBM is going to get a billion dollars to establish a new Quantum Foundry uh subsidiary. So that's a foundry to actually make these chips. 00:32 Speaker A All these companies are developing these chips. Um Intel or excuse me, IBM is actually going to be making them. 00:41 Speaker A Global Foundries will get another $375 million. and then most of the other firms are going to be getting $100 million in order to advance their research on their various parts of the Quantum universe that they're looking at here. 01:05 Speaker A I had the chance to talk to IBM's vice president of Quantum adoption and business development, that's Scott Crowder. 01:13 Speaker A We talked about what this is going to look like. There's not many details of it yet, but the government's going to put in a billion, IBM is going to put in a billion, and he really talked about that this is a look to the future. 01:26 Speaker A He said, they may not be a barrier today, that is supply chains, but beginning in the 2030s, we need a secure manufacturing supply chain for the wafers we need for quantum computers. 01:38 Speaker A IBM already has a facility up in Albany, New York that makes chips and makes the quantum chips that they're working on. 01:50 Speaker A He really said that you know, they will use that facility and then expand as needed. 01:57 Speaker A There's a different mix of equipment that is better suited to making quantum than to making other types of more classic um computing chips and so they'll pivot more to that. 02:08 Speaker A Um and he really said that it is the 2030s when he expects this to sort of ramp up in a more dramatic fashion. ...
Stefan Sutka Dell Technologies ( DELL ) and HP ( HPQ ) shares surged on Friday after PC maker Lenovo reported stronger-than-expected results. Dell shares rose more than 15% in morning trading, while HP tacked on 14%. Lenovo reported fourth-quarter results that showed revenue surged 27% year-over-year to $21.6B, while adjusted net income jumped 101%. The company benefited from the ongoing PC recove...
Stefan Sutka Dell Technologies ( DELL ) and HP ( HPQ ) shares surged on Friday after PC maker Lenovo reported stronger-than-expected results. Dell shares rose more than 15% in morning trading, while HP tacked on 14%. Lenovo reported fourth-quarter results that showed revenue surged 27% year-over-year to $21.6B, while adjusted net income jumped 101%. The company benefited from the ongoing PC recovery and AI services and services business. Its Intelligent Devices Group rose 24% year-over-year to generate $14.6B in revenue, while AI-related revenue surged 84% year-over-year. Separately, on Friday, Wells Fargo upped its price target on Dell to $270 from $180, as analyst Aaron Rakers said he expects the tech giant to keep benefiting from artificial intelligence. “We expect Dell to increase its FY27 guide on demand acceleration across AI infrastructure,” Rakers wrote in a note to clients. Rakers has an Overweight rating on Dell. On Thursday, Morgan Stanley raised its price target on Dell to $170 from $110 but remained cautious on profitability for the second half of the year. Dell shares have gained 20% over the past five trading sessions and have risen more than 36% over the past month. HP shares have gained 19% over the past five trading sessions and have risen more than 22% over the past month. Dell is set to report its upcoming first-quarter results on May 28, and HP is set to report its fiscal second-quarter results on May 27. A consensus of analysts expects Dell to earn $2.96 per share on $35.75B in revenue, while HP is expected to earn $0.72 per share on $14.07B in revenue. More on Dell and HP Dell Brings Hybrid AI Vision To Life Dell: The Stock Is Pricey But I'm Still Dipping Into The Buys Dell Q1 Preview: Upcoming Earnings Could Extend AI Momentum Dell's price target raised at Morgan Stanley, but analysts remain cautious Dell Technologies seen as 'well positioned' for next phase of enterprise AI: Evercore
'Mission Impossible' Begins: Watch Live As Kevin Warsh Is Sworn In As 17th Fed Chair Kevin Warsh, who’s promised the biggest shakeup in decades at the US central bank, is set to be sworn into office this morning at 1100ET in a White House ceremony as the 17th chair of the Federal Reserve. Warsh takes over at a tense moment for the economy and the central bank . Inflation has reaccelerated, driven ...
'Mission Impossible' Begins: Watch Live As Kevin Warsh Is Sworn In As 17th Fed Chair Kevin Warsh, who’s promised the biggest shakeup in decades at the US central bank, is set to be sworn into office this morning at 1100ET in a White House ceremony as the 17th chair of the Federal Reserve. Warsh takes over at a tense moment for the economy and the central bank . Inflation has reaccelerated, driven by the impact of war in the Middle East on energy supplies. The Fed, meanwhile, has been battered by President Donald Trump for not cutting interest rates quickly enough. That backdrop of persistent inflation and political pressure has stoked concern among investors and analysts that the Fed’s independence is under threat. In his confirmation hearing for the job, Warsh repeatedly pledged to act independently even as he criticized the central bank for what he called mission creep and its response to the pandemic inflation surge. Warsh faces the highest 10Y yield of any Fed Chair being sworn in since Greenspan and a market that is priced dramatically more hawkishly than The Fed's 'dots' expected... For those watching closely, the first sign of new management will likely be visible in the Fed’s communication about monetary policy . The June 17 press conference could give us a first taste. Warsh has promised less forward guidance, data dependence and near-term forecasting, and more dissent. This would be a structural break from the Bernanke-Yellen-Powell years. Warsh's swearing-in ceremony is due to start at 1100ET... As James E Thorne wrote on X , Kevin Warsh’s arrival at the Federal Reserve is not a personnel change. It is a regime change attempt inside an institution built to prevent one. A supply-sider now runs a central bank hard-wired for Keynesian demand management, and the machine is already resisting the new code. The next mistake is visible in plain sight. Keynesians on Wall Street and inside the Fed are treating a supply shock as if it were a demand boom and calling ...